Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (48)

2024

  1. A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24

    BJU International, Vol. 134, Núm. 4, pp. 568-577

  2. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

  3. Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

    Archivos de Bronconeumologia, Vol. 60, Núm. 8, pp. 537-538

  4. Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?

    Cancers, Vol. 16, Núm. 13

  5. Is trimodal therapy the current standard for muscle-invasive bladder cancer?

    Actas Urologicas Espanolas, Vol. 48, Núm. 5, pp. 345-355

  6. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

    European urology oncology, Vol. 7, Núm. 3, pp. 462-468

  7. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection

    Actas Urologicas Espanolas, Vol. 48, Núm. 9, pp. 623-631

  8. Stereotactic body radiation therapy (SBRT): a new treatment option in renal cancer

    Actas Urologicas Espanolas

  9. Total Neoadjuvant Therapy Approach for the Treatment of Locally Advanced Rectal Cancer: Where Do We Stand?

    Oncology (Switzerland), Vol. 102, Núm. 7, pp. 646-657

2023

  1. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

    Clinical Oncology, Vol. 35, Núm. 12, pp. e676-e688

  2. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

  3. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors in Locally Advanced Rectal Cancer

    Oncology (Switzerland), Vol. 101, Núm. 6, pp. 349-357

  4. Novel Approaches in the Systemic Management of High-Risk Prostate Cancer

    Clinical Genitourinary Cancer, Vol. 21, Núm. 6, pp. e485-e494

  5. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  6. PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

    Clinical and Translational Imaging, Vol. 11, Núm. 3, pp. 241-254

  7. Prostate Cancer: Management of Biochemical Recurrence after Surgery

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 733-745

  8. Radioterapia en etapas precoces del cáncer de pulmón

    Revisiones en Cancer, Vol. 37, Núm. 3, pp. 133-147

  9. Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 718-732

  10. Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time?

    Clinical Oncology, Vol. 35, Núm. 3, pp. 163-176

  11. Stereotactic body radiation therapy for kidney cancer. Where do we stand?

    International Journal of Urology, Vol. 30, Núm. 5, pp. 437-445